# A case report of HER2-positive descending colon cancer with peritoneal metastasis and literature review

## TL;DR

A 26-year-old man with HER2-positive colon cancer and peritoneal metastasis showed significant improvement after anti-HER2 therapy and surgery, achieving a 56-month survival.

## Contribution

This case report highlights the effectiveness of Trastuzumab Deruxtecan in treating HER2-positive descending colon cancer with metastasis.

## Key findings

- Trastuzumab Deruxtecan significantly reduced metastatic foci in the patient.
- The patient achieved a tumor-free state after chemotherapy and surgical resection.
- The patient's survival period reached 56 months, indicating a positive treatment outcome.

## Abstract

Human epidermal growth factor receptor 2 (HER2) is an anti-cancer drug target for colon cancer. Among patients with colorectal malignancy (colorectal cancer, CRC), those with HER2 mutations have a poor overall prognosis and a significantly increased drug resistance. In recent years, anti-HER2 therapeutic drugs have developed rapidly. According to several clinical studies and case reports, anti-HER2 therapy, as an emerging anti-cancer approach, plays a crucial role in the treatment of HER2-positive CRC patients. Here, we present a case of HER2-positive descending colon cancer with peritoneal metastasis. The patient is a 26-year-old male, diagnosed with malignant tumor of the descending colon with peritoneal metastasis in April 2020. After multiple treatment modalities, the disease progressed. After chemotherapy with Trastuzumab Deruxtecan (T-DXd/DS-8201), the metastatic foci significantly shrank, and after surgical resection, a tumor-free state (NED) was achieved. Up to now, the patient’s survival period has reached 56 months.